Faculty profile

Xiaoyan Jiang

ResearcherTerry Fox LaboratoryUniversity of British Columbia

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of British Columbia directory, so their courses and email address may be missing. Find their university profile.

Xiaoyan Jiang

Researcher

Terry Fox Laboratory

Health Sciences

University of British Columbia

Vancouver, British Columbia, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
15 publications in the last five years, latest in 2025.
Senior (last) author on 9 recent papers, a sign of leading a research group.
Principal investigator on 5 research grants (5 CIHR), most recently in 2022.
Supervised 3 trainees who won CIHR awards, most recently in 2018.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

5,052

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Drug Resistance Leukemic Stem Cells Tyrosine Kinase Inhibitors Chronic Myeloid Leukemia Bcr-Abl Combination Therapies Patient-Derived Leukemia Xenotransplant Model Acute Myeloid Leukemia (Aml)

Latest papers

A novel regulatory circuit of ATG4B and SESN3 promotes T cell leukemogenesis.
Journal of experimental & clinical cancer research : CR · 2025
Dual Targeting of Smoothened, a Key Regulator in the Hedgehog Pathway, and BCR-ABL1 Effectively Eradicates Drug-Insensitive Stem/Progenitor Cells in Chronic Myeloid Leukemia.
Cells · 2025 · senior author
Suppressing t(4;11) Acute Leukemia by Lipopolymer Nanoparticle Delivery of siRNA Targeting KMT2A::AFF1 with Enhanced Extrahepatic Delivery.
Advanced healthcare materials · 2025

All 56 publications

Latest funding

A novel oncolytic virotherapy to overcome drug-resistance in acute myeloid leukemia
CIHR · 2022 · Nominated PI
$100,000
Synthetic Biomaterials to Package and Deliver siRNA Nanoparticles in order to Curb Uncontrolled Growth of Leukemic Cells
CIHR · 2020 · Co-investigator
$757,350
Targeting a novel miR-185/PAK6 axis to overcome drug-resistance in human leukemia
CIHR · 2019 · Nominated PI
$902,700

All 12 grants and awards

56 publications.

A novel regulatory circuit of ATG4B and SESN3 promotes T cell leukemogenesis.

Ma W, Zhang L, Zhou H, Zhang X, Qin X, Wan Y, Ma R, Song X, Zhou X, Liu H, Hu B, Wu D, Wang J, Jiang X, Zhao Y

Journal of experimental & clinical cancer research : CR2025

DOI: 10.1186/s13046-025-03588-0 PMID: 41275290

Dual Targeting of Smoothened, a Key Regulator in the Hedgehog Pathway, and BCR-ABL1 Effectively Eradicates Drug-Insensitive Stem/Progenitor Cells in Chronic Myeloid Leukemia.

Turner KA, Chen M, Rothe K, Forrest DL, Jiang X

Cells2025Senior author

DOI: 10.3390/cells14191565 PMID: 41090792

Suppressing t(4;11) Acute Leukemia by Lipopolymer Nanoparticle Delivery of siRNA Targeting KMT2A::AFF1 with Enhanced Extrahepatic Delivery.

Nasrullah M, Kc R, Rajendran AP, Dezfouli SA, Kucharski C, Jiang X, Gibson SB, Brandwein J, Heidenreich O, Uludağ H

Advanced healthcare materials2025

DOI: 10.1002/adhm.202502019 PMID: 40685918

Identification of a PAK6-Mediated MDM2/p21 Axis That Modulates Survival and Cell Cycle Control of Drug-Resistant Stem/Progenitor Cells in Chronic Myeloid Leukemia.

Wu A, Chen M, Phoa A, Yang Z, Forrest DL, Jiang X

International journal of molecular sciences2025Senior author

DOI: 10.3390/ijms26136533 PMID: 40650306

Lipopolymers as the Basis of Non-Viral Delivery of Therapeutic siRNA Nanoparticles in a Leukemia (MOLM-13) Model.

Yotsomnuk P, Rajendran AP, Sundaram DNM, Morales LC, Kucharski C, Nasrullah M, Skolpap W, Jiang X, Gibson SB, Brandwein J, Uludağ H

Biomolecules2025

DOI: 10.3390/biom15010115 PMID: 39858509

Lipopolymer/siRNA complexes engineered for optimal molecular and functional response with chemotherapy in FLT3-mutated acute myeloid leukemia.

Ansari AS, Kucharski C, Kc R, Nisakar D, Rahim R, Jiang X, Brandwein J, Uludağ H

Acta biomaterialia2024

DOI: 10.1016/j.actbio.2024.08.053 PMID: 39236794

Lipopolymer/siRNA Nanoparticles Targeting the Signal Transducer and Activator of Transcription 5A Disrupts Proliferation of Acute Lymphoblastic Leukemia.

Nasrullah M, Kc R, Nickel K, Parent K, Kucharski C, Meenakshi Sundaram DN, Rajendran AP, Jiang X, Brandwein J, Uludağ H

ACS pharmacology & translational science2024

DOI: 10.1021/acsptsci.4c00336 PMID: 39296267

Clinical Insights into Structure, Regulation, and Targeting of ABL Kinases in Human Leukemia.

Wu A, Liu X, Fruhstorfer C, Jiang X

International journal of molecular sciences2024Senior author

DOI: 10.3390/ijms25063307 PMID: 38542279

Lipopolymer mediated siRNA delivery targeting aberrant oncogenes for effective therapy of myeloid leukemia in preclinical animal models.

Ansari AS, K C R, Morales LC, Nasrullah M, Meenakshi Sundaram DN, Kucharski C, Jiang X, Brandwein J, Uludağ H

Journal of controlled release : official journal of the Controlled Release Society2024

DOI: 10.1016/j.jconrel.2024.02.018 PMID: 38360178

Identification of multivariable microRNA and clinical biomarker panels to predict imatinib response in chronic myeloid leukemia at diagnosis.

Wu A, Yen R, Grasedieck S, Lin H, Nakamoto H, Forrest DL, Eaves CJ, Jiang X

Leukemia2023Senior author

DOI: 10.1038/s41375-023-02062-0 PMID: 37848633

Something wrong or missing on this profile? Suggest a correction

Xiaoyan Jiang

Research

Latest papers

Latest funding

A novel regulatory circuit of ATG4B and SESN3 promotes T cell leukemogenesis.

Dual Targeting of Smoothened, a Key Regulator in the Hedgehog Pathway, and BCR-ABL1 Effectively Eradicates Drug-Insensitive Stem/Progenitor Cells in Chronic Myeloid Leukemia.

Suppressing t(4;11) Acute Leukemia by Lipopolymer Nanoparticle Delivery of siRNA Targeting KMT2A::AFF1 with Enhanced Extrahepatic Delivery.

Identification of a PAK6-Mediated MDM2/p21 Axis That Modulates Survival and Cell Cycle Control of Drug-Resistant Stem/Progenitor Cells in Chronic Myeloid Leukemia.

Lipopolymers as the Basis of Non-Viral Delivery of Therapeutic siRNA Nanoparticles in a Leukemia (MOLM-13) Model.

Lipopolymer/siRNA complexes engineered for optimal molecular and functional response with chemotherapy in FLT3-mutated acute myeloid leukemia.

Lipopolymer/siRNA Nanoparticles Targeting the Signal Transducer and Activator of Transcription 5A Disrupts Proliferation of Acute Lymphoblastic Leukemia.

Clinical Insights into Structure, Regulation, and Targeting of ABL Kinases in Human Leukemia.

Lipopolymer mediated siRNA delivery targeting aberrant oncogenes for effective therapy of myeloid leukemia in preclinical animal models.

Identification of multivariable microRNA and clinical biomarker panels to predict imatinib response in chronic myeloid leukemia at diagnosis.

Frequent collaborators

Connie Eaves

Youwen Zhou

Hasan Uludag

Michel Roberge

Inanc Birol

Steve Jean

Dusica Maysinger

Khosrow Adeli

Ivan Topisirovic

Martin Gleave

Marcel Bally

Arnim Pause

Ivan Topisirovic

Xi-Long Zheng

Urban Emmenegger

Emily Pang

Michael Sacher

Ruth Slack

Craig McCormick

Afsaneh Lavasanifar

Honglin Luo

Filip Van Petegem

Calvin Yip

Shoukat Dedhar

Eldad Zacksenhaus

Isabella Caniggia

Andre Bedard

Michael Weinfeld

John Lee

Ryan Brinkman